End-to-End Solution for Digital Pathology w/ Leif Honda, TriMetis Life Sciences

In digital pathology is it  best to start small and incrementally implement the technology or go all in to reap all the the benefits at once?

The good news is that those two approaches are not mutually exclusive, you can totally start small and scale up, and you can do it with just one vendor partner if you feel like it!

This episode's guest is Leif Honda, Chief Innovation Officer at TriMetis Life Sciences. TriMetis is a unique company that serves as an external hub for those who want to start digital pathology but do not have all the components.

In an ideal world, going all-in would be the best option, but due to the high costs, it may be better to start small and work with partnering companies to take advantage of the full infrastructure and TriMetic can help with that. 

Leif has an extraordinary background - he has a molecular biology and economic degree. This combination positions him perfectly to be the Chief Innovation Officer. 

TriMetis started as a biobank, and started leveraging digital pathology to digitize the H&E slides of their biobank samples. Later they started using image analysis to quantify the amount and type of tissue present in their biobanking samples. Then they offered this type of service to other biobanks and other research institutions. 

They are on a mission to accelerate cancer research through facilitating access to the relevant bio-specimen for everyone who needs them. Currently they also enable the image analysis algorithm creators to deliver their algorithms to cancer researchers and deploy them through the TriMetis digital platform. 

All these developments make TriMetis an End-to-End digital pathology solution for cancer researchers. 

Listen to the full episode to learn more about how you can benefit from their work. 

THIS EPISODE'S RESOURCES:

Support the Show.

Become a Digital Pathology Trailblazer and See you inside the club: Digital Pathology Club Membership